Guideline based treatment of invasive aspergillosis;Leitliniengerechte Therapie der invasiven Aspergillose

Mycoses

Volumn 53, Issue SUPPL. 1, 2010, Pages 36-43

  Karthaus, M ^a  

^a Klinikum Neuperlach   (Germany)

Author keywords

Evidence based treatment; Immunocompromized patients; Infection; Invasive aspergillosis; Treatment guideline

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE ASPERGOLLOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; AZOLES; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ECHINOCANDINS; HUMANS; IMMUNOCOMPROMISED HOST; PRACTICE GUIDELINES AS TOPIC;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; EMERICELLA NIDULANS; FUNGI;

EID: 77649199037     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01840.x     Document Type: Review

References (25)

1. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 360.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 803.
3. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002 16 : 875 894.
4. Maschmeyer G, Neuburger S, Fritz L et al. On behalf of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 2009 20 : 1560 1564.
5. Krüger WH, Zöllner B, Kaulfers PM, Zander AR. Effective protection of allogeneic stem cell recipients against Aspergillosis by HEPA air filtration during a period of construction - a prospective survey. J Hematother Stem Cell Res 2003 12 : 301 307.
6. Herbrecht R, Denning DW, Patterson TF et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 415. (Pubitemid 34851833)
7. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008 112 : 2309 2312.
8. Karthaus M. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002 347 : 2080 2081.
9. Jansen JP, Kern WV, Cornely OA et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006 9 : 12 23.
10. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 106 : 2641 2645.
11. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 1297.
12. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997 157 : 1857 1862.
13. Caillot D, Bassaris H, McGeer A et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001 33 : e83 90.
14. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 1571.
15. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 107 : 2888 2897.
16. Caillot D, Thiébaut A, Herbrecht R et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007 110 : 2740 2746.
17. Denning DW, Marr KA, Lau WM et al. Micafungin (FK 463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 349.
18. Spreghini E, Orlando F, Santinelli A et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob Agents Chemother 2009 53 : 4035 4039.
19. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
20. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009 88 : 97 110.
21. Davis LE. Fungal infections of the central nervous system. Neurol Clin 1999 17 : 761 781.
22. Ruhnke M, Kofla G, Otto K, Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007 21 : 659 676.
23. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 2007 50 : 196 200.
24. De Pauw B, Walsh TJ, Donnelly JP et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 46 : 1813 1821.
25. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009 64 : 1274 1281.